Are you over 18 and want to see adult content?
More Annotations
A complete backup of calvinseminary.edu
Are you over 18 and want to see adult content?
A complete backup of spywareinfoforum.com
Are you over 18 and want to see adult content?
A complete backup of urbanadventurequest.com
Are you over 18 and want to see adult content?
A complete backup of drmasoudebadi.com
Are you over 18 and want to see adult content?
A complete backup of michaelkors.com.de
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of donthatethegeek.com
Are you over 18 and want to see adult content?
A complete backup of diamondedgecapital.com
Are you over 18 and want to see adult content?
A complete backup of shannonfabrics.com
Are you over 18 and want to see adult content?
A complete backup of lantechnology-eg.com
Are you over 18 and want to see adult content?
A complete backup of thegailygrind.com
Are you over 18 and want to see adult content?
Text
CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and ChiefSEC FILINGS
SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine EfficacyCAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and ChiefSEC FILINGS
SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to aLIVE | NOVAVAX
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services.INVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine Efficacy NOVAVAX TO HOST MARYLAND GOVERNOR LARRY HOGAN AT SITE OF GAITHERSBURG, Md., June 9, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, will host Maryland Governor Larry Hogan at the site of the company's planned Vaccines Innovation Campus and global headquarters in Gaithersburg on Thursday, June 10 at 9:30 AMET.
NOVAVAX ANNOUNCES POSITIVE DATA FROM THREE COMPLEMENTARY 16 hours ago · GAITHERSBURG, Md., June 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preclinical and clinical data on the company's recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta (B.1.351) variant, which was originally GSK TO SUPPORT MANUFACTURE OF NOVAVAX' COVID-19 VACCINE GSK is working with German mRNA specialist, CureVac, to jointly develop next generation, multi-valent mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine. GSK will also support manufacturing of up to 100m doses of CureVac's first generation COVID-19 vaccine at our facilities in Belgium.STOCK QUOTE
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. NOVAVAX TO PARTICIPATE IN PANEL AT BIO DIGITAL 2021 GAITHERSBURG, Md., June 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14.BIO Digital 2021 is hosted by the HISTORICAL PRICE LOOKUP 1:1. $151.29. $154.40. $147.11. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shownabove.
NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine Efficacy NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief MALARIA VACCINE PHASE 2B CLINICAL TRIAL RESULTS PUBLISHED GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includesSEC FILINGS
SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine Efficacy NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief MALARIA VACCINE PHASE 2B CLINICAL TRIAL RESULTS PUBLISHED GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includesSEC FILINGS
SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to aLIVE | NOVAVAX
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services.INVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine EfficacyCAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
NOVAVAX TO HOST MARYLAND GOVERNOR LARRY HOGAN AT SITE OF GAITHERSBURG, Md., June 9, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, will host Maryland Governor Larry Hogan at the site of the company's planned Vaccines Innovation Campus and global headquarters in Gaithersburg on Thursday, June 10 at 9:30 AMET.
NOVAVAX TO PARTICIPATE IN PANEL AT BIO DIGITAL 2021 GAITHERSBURG, Md., June 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14.BIO Digital 2021 is hosted by the NOVAVAX ANNOUNCES POSITIVE DATA FROM THREE COMPLEMENTARY 5 hours ago · GAITHERSBURG, Md., June 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preclinical and clinical data on the company's recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta (B.1.351) variant, which was originally GSK TO SUPPORT MANUFACTURE OF NOVAVAX' COVID-19 VACCINE GSK is working with German mRNA specialist, CureVac, to jointly develop next generation, multi-valent mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine. GSK will also support manufacturing of up to 100m doses of CureVac's first generation COVID-19 vaccine at our facilities in Belgium.STOCK QUOTE
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. HISTORICAL PRICE LOOKUP 1:1. $151.29. $154.40. $147.11. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shownabove.
NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine EfficacyINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
NOVAVAX COMPLETES ENROLLMENT OF PREVENT-19, COVID-19 PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico; GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States andSTOCK QUOTE
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine EfficacyINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
NOVAVAX COMPLETES ENROLLMENT OF PREVENT-19, COVID-19 PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico; GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States andSTOCK QUOTE
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services.LIVE | NOVAVAX
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services.INVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
COVID-19 PROGRAM UPDATE WORLD VACCINE CONGRESS novavax.com 7 Final Primary Analysis: 90% Overall Efficacy NVX-CoV2373 (n=7,020) Placebo (n=7,020) Total 10 96 Mild 1 28 Moderate 9 63 Severe 0 5 Vaccine Efficacy COVID-19 VACCINE CANDIDATE TRIALS This COVID-19 clinical trial is testing whether the investigational vaccine, NVX-CoV2373 will prevent COVID-19. COVID-19 is a global health crisis, and safe and effective vaccines are critical to ending the pandemic. The PREVENT-19 (PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) clinical trial will enroll up to30,000
CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CORONAVIRUS VACCINE UPDATES GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. NOVAVAX TO HOST MARYLAND GOVERNOR LARRY HOGAN AT SITE OF 1 day ago · GAITHERSBURG, Md., June 9, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, will host Maryland Governor Larry Hogan at the site of the company's planned Vaccines Innovation Campus and global headquarters in Gaithersburg on Thursday, June 10 at 9:30 AM ET. NOVAVAX PROVIDES PHASE 3 COVID-19 VACCINE CLINICAL GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusionprotein made
NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief NOVAVAX TO PARTICIPATE IN PANEL AT BIO DIGITAL 2021 GAITHERSBURG, Md., June 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14.BIO Digital 2021 is hosted by the NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process EVENTS | INVESTOR RELATIONS | NOVAVAX INC. Novavax at Cowen and Company Healthcare Conference. Mar 08, 2010 from 4:45 PM to 4:45 PM EST. Novavax at The 8th Annual BIO Investor Forum. Oct 29, 2009 from 11:00 AM to 11:00 AM PDT. Novavax at Piper Jaffray Second Annual London Health Care Conference. JunSEC FILINGS
SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NANOFLU™ VACCINE UPDATE: PHASE 3 RESULTS The NanoFlu vaccine: Recombinant hemagglutinin (HA) nanoparticles • Produced in a Baculovirus/Sf9 insect cell system • Expressed as recombinant, full-length, wild-type, uncleaved HA0 that assembles into homotrimers • Purified homotrimers form higher order nanoparticle structures of 20-40 nm with PS-80 • Manufactured in a rapid, high-yield, high purity, process EVENTS | INVESTOR RELATIONS | NOVAVAX INC. Novavax at Cowen and Company Healthcare Conference. Mar 08, 2010 from 4:45 PM to 4:45 PM EST. Novavax at The 8th Annual BIO Investor Forum. Oct 29, 2009 from 11:00 AM to 11:00 AM PDT. Novavax at Piper Jaffray Second Annual London Health Care Conference. JunSEC FILINGS
SEC Filings. Quarterly report which provides a continuing view of a company's financial position. Official notification to shareholders of matters to be brought to a URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. TRANSFORMATIONAL VACCINES CREATED AT NOVAVAX Ebola virus (EBOV) EBOV is a filovirus that produces severe, often fatal illness in humans. Within the last decade, it has produced two large outbreaks in sub-Saharan Africa with high mortality rates. The FDA approved the Ebola vaccine rVSV-ZEBOV (tradename “Ervebo”) on December 19, 2019. Although it's not in active development, our Ebola PIPELINE IS ROBUST AT NOVAVAX In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) across 19 clinical sites in the United GSK TO SUPPORT MANUFACTURE OF NOVAVAX' COVID-19 VACCINE GSK is working with German mRNA specialist, CureVac, to jointly develop next generation, multi-valent mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine. GSK will also support manufacturing of up to 100m doses of CureVac's first generation COVID-19 vaccine at our facilities in Belgium. NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 3.0 – 23 December 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
MALARIA VACCINE PHASE 2B CLINICAL TRIAL RESULTS PUBLISHED GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes HISTORICAL PRICE LOOKUP 1:1. $151.29. $154.40. $147.11. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shownabove.
POSTER #69 IN-DEPTH ANALYTICAL CHARACTERIZATION AND In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine EL Maynard1, D Scott1, O Borisov1, G Smith1, JE Curtis2, A Grishaev2, S Krueger2 1Novavax, Inc., Gaithersburg, MD 2National Institute of Standards and Technology, Gaithersburg, MD RESULTS RESULTS 1. August, A, Glenn, GM, et al. NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. TRANSFORMATIONAL VACCINES CREATED AT NOVAVAX Ebola virus (EBOV) EBOV is a filovirus that produces severe, often fatal illness in humans. Within the last decade, it has produced two large outbreaks in sub-Saharan Africa with high mortality rates. The FDA approved the Ebola vaccine rVSV-ZEBOV (tradename “Ervebo”) on December 19, 2019. Although it's not in active development, our Ebola PIPELINE IS ROBUST AT NOVAVAX In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) across 19 clinical sites in the United GSK TO SUPPORT MANUFACTURE OF NOVAVAX' COVID-19 VACCINE GSK is working with German mRNA specialist, CureVac, to jointly develop next generation, multi-valent mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine. GSK will also support manufacturing of up to 100m doses of CureVac's first generation COVID-19 vaccine at our facilities in Belgium. NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 3.0 – 23 December 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
MALARIA VACCINE PHASE 2B CLINICAL TRIAL RESULTS PUBLISHED GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes HISTORICAL PRICE LOOKUP 1:1. $151.29. $154.40. $147.11. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shownabove.
POSTER #69 IN-DEPTH ANALYTICAL CHARACTERIZATION AND In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine EL Maynard1, D Scott1, O Borisov1, G Smith1, JE Curtis2, A Grishaev2, S Krueger2 1Novavax, Inc., Gaithersburg, MD 2National Institute of Standards and Technology, Gaithersburg, MD RESULTS RESULTS 1. August, A, Glenn, GM, et al. NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. TRANSFORMATIONAL VACCINES CREATED AT NOVAVAX Ebola virus (EBOV) EBOV is a filovirus that produces severe, often fatal illness in humans. Within the last decade, it has produced two large outbreaks in sub-Saharan Africa with high mortality rates. The FDA approved the Ebola vaccine rVSV-ZEBOV (tradename “Ervebo”) on December 19, 2019. Although it's not in active development, our Ebola PIPELINE IS ROBUST AT NOVAVAX In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) across 19 clinical sites in the United GSK TO SUPPORT MANUFACTURE OF NOVAVAX' COVID-19 VACCINE GSK is working with German mRNA specialist, CureVac, to jointly develop next generation, multi-valent mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine. GSK will also support manufacturing of up to 100m doses of CureVac's first generation COVID-19 vaccine at our facilities in Belgium. NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 3.0 – 23 December 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
MALARIA VACCINE PHASE 2B CLINICAL TRIAL RESULTS PUBLISHED GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes HISTORICAL PRICE LOOKUP 1:1. $151.29. $154.40. $147.11. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shownabove.
POSTER #69 IN-DEPTH ANALYTICAL CHARACTERIZATION AND In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine EL Maynard1, D Scott1, O Borisov1, G Smith1, JE Curtis2, A Grishaev2, S Krueger2 1Novavax, Inc., Gaithersburg, MD 2National Institute of Standards and Technology, Gaithersburg, MD RESULTS RESULTS 1. August, A, Glenn, GM, et al. NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
NEW GENERATION OF REVOLUTIONARY VACCINES ADVANCED BY NOVAVAXFOR INVESTORSNEWSCAREERSCONTACT USABOUT USOUR PIPELINE An agile and determined team. Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some ofINVESTOR RELATIONS
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Latest InvestorPresentation.
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.CAREERS AT NOVAVAX
SuperNOVAs come first. Our commitment to promoting health and wellness in our employees starts with our own community. We value balance, encourage growth, and recognize you are our most important asset. Join a team where your contribution makes a difference to your community and the world. We ensure our SuperNOVAs thrive in and out of theoffice.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 2.0 – 23 October 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
PRESS RELEASES & STATEMENTS 5/3/2021. Download. Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021. Corporate and Finance. 4/23/2021. Download. Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet. Matrix-M™ Adjuvant. 4/23/2021. NOVAVAX ANNOUNCES POSITIVE PRECLINICAL DATA FOR - Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus-Data shared via
URGENT GLOBAL HEALTH NEEDS ADDRESSED BY NOVAVAX Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date. TRANSFORMATIONAL VACCINES CREATED AT NOVAVAX Ebola virus (EBOV) EBOV is a filovirus that produces severe, often fatal illness in humans. Within the last decade, it has produced two large outbreaks in sub-Saharan Africa with high mortality rates. The FDA approved the Ebola vaccine rVSV-ZEBOV (tradename “Ervebo”) on December 19, 2019. Although it's not in active development, our Ebola PIPELINE IS ROBUST AT NOVAVAX In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) across 19 clinical sites in the United GSK TO SUPPORT MANUFACTURE OF NOVAVAX' COVID-19 VACCINE GSK is working with German mRNA specialist, CureVac, to jointly develop next generation, multi-valent mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine. GSK will also support manufacturing of up to 100m doses of CureVac's first generation COVID-19 vaccine at our facilities in Belgium. NOVAVAX ANNOUNCES LEADERSHIP UPDATES Novavax Announces Leadership Updates. GAITHERSBURG, Md., April 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the promotion of Gale E. Smith, Ph.D., to Senior Vice President, Discovery and Pre-Clinical Research and Chief NOVAVAX STATEMENT ON PROOF OF VACCINATION FOR PHASE 3 In the U.K., the National Health Service (NHS), Vaccines Task Force (VTF) and National Institute for Health Research (NIHR), are working to ensure that all who received NVX-CoV2373 will have their vaccination dates entered into the NHS App.For the most current information and status, please visit Important information for participants in light of COVID-19 vaccine deployment on the NIHRwebsite.
CONFIDENTIAL
SARS-CoV-2 rS Vaccine Confidential Protocol No. 2019nCoV -302 Novavax, Inc. Version 3.0 – 23 December 2020 Page 4 . INVESTIGATOR PROTOCOLAGREEMENT PAGE
MALARIA VACCINE PHASE 2B CLINICAL TRIAL RESULTS PUBLISHED GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes HISTORICAL PRICE LOOKUP 1:1. $151.29. $154.40. $147.11. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shownabove.
POSTER #69 IN-DEPTH ANALYTICAL CHARACTERIZATION AND In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine EL Maynard1, D Scott1, O Borisov1, G Smith1, JE Curtis2, A Grishaev2, S Krueger2 1Novavax, Inc., Gaithersburg, MD 2National Institute of Standards and Technology, Gaithersburg, MD RESULTS RESULTS 1. August, A, Glenn, GM, et al.* About Us
ABOUT NOVAVAX
Novavax has developed a platform upon which we can manufacture a variety of proprietary recombinant nanoparticle vaccines.Learn More
* About Us
* Board of Directors* Management Team
* Contact Us
* Careers
* Pipeline
PIPELINE
Novavax’ clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.Learn More
* Clinical Stage Pipeline* Clinical Trials
* Scientific
Presentations
* Scientific
Posters
* Vaccine Technology * Matrix-M™ Adjuvant Technology* Publications
* RFP Announcement
* Partners
* Cadila Pharmaceuticals Collaboration * Bill & Melinda Gates Foundation * Business Development Contact* Investors
INVESTORS
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectiousdisease.
Learn More
* CORPORATE GOVERNANCE * Investor Presentation* Stock Information
* Events
* SEC Filings
* 2019 Annual Report* Analyst Coverage
* Investor Relations Contact * Join Our Press Release List* News
NEWS
Learn More
* Press Releases
* Join Our
Press Release List
* Novavax in the news* Contact Us
*
*
*
1
PrevNext
ABOUT NOVAVAX
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging diseasethreats. More...
INVESTORS
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectiousdisease. More...
Latest Scientific Presentations Latest Scientific Posters Most Recent Corporate UpdateIN THE NEWS
NOVAVAX REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS05/11/2020
NOVAVAX TO RECEIVE UP TO $388 MILLION FUNDING FROM CEPI FOR COVID-19 VACCINE DEVELOPMENT AND MANUFACTURING05/11/2020
NOVAVAX TO PRESENT COVID-19 VACCINE CANDIDATE PROGRESS IN WORLD VACCINE CONGRESS WEBINAR SERIES05/11/2020
ABOUT US
* About Us
* Board of Directors* Management Team
* Contact Us
* Careers
PIPELINE
* Clinical Stage Pipeline* Clinical Trials
* Presentations
* Vaccine Technology * Matrix-M™ Adjuvant Technology* Publications
* RFP Announcement
* Partners
* Cadila Pharmaceuticals Collaboration * Bill & Melinda Gates Foundation * Business Development ContactINVESTORS
* CORPORATE GOVERNANCE * INVESTOR PRESENTATION* STOCK INFORMATION
* Events
* SEC Filings
* ANALYST COVERAGE
* INVESTOR RELATIONS CONTACT * Join Our Press Release ListNEWS
* Press Releases
* JOIN OUR PRESS RELEASE LIST * Novavax in the News* CONTACT US
CONTACT US
21 Firstfield Road
Gaithersburg, MD 20878 Phone (240) 268-2000 Privacy Policy | Terms and Conditions Pay Transparency Nondiscrimination Provision Purchase Order Terms & ConditionsFOLLOW US:
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0